Sat.May 11, 2024 - Fri.May 17, 2024

article thumbnail

It’s Past Time to Prevent Polypharmacy in U.S. Healthcare

MedCity News

The dangers of polypharmacy and its increasingly wide reach across the American population make it imperative that we enhance the accuracy and efficiency of medication reconciliation processes. The post It’s Past Time to Prevent Polypharmacy in U.S. Healthcare appeared first on MedCity News.

article thumbnail

With 4-year data, Novo bolsters star power of obesity blockbuster Wegovy

Fierce Pharma

With new four-year data in hand, Novo Nordisk can make a case for its popular obesity med Wegovy to be used as a long-term treatment. | An analysis unveiled at the European Congress on Obesity showed that Wegovy patients lost 10% of their weight, on average, over a 4-year span.

Patients 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

5 trends impacting drug spend in the U.S.

PharmaVoice

Key factors changing how much Americans spend on prescriptions.

article thumbnail

Sales Negotiation Skills That Deliver Success

Integrity Solutions

For many in sales, negotiation is one of the most challenging aspects of the job. More often than not, these salespeople approach negotiation as a win-or-lose endurance game, a contentious battle that pits two opposing sides against each other. “Winning” means convincing the customer to accept your point of view—even if the outcome isn’t necessarily in the customer’s best interest.

Sales 238
article thumbnail

State of AI in Sales & Marketing 2025

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

article thumbnail

Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval

MedCity News

Amgen’s Imdelltra has FDA approval in extensive-stage small cell lung cancer, making it the first bispecific T cell engager approved for treating this type of cancer. Analysts project the new Amgen drug will become a blockbuster seller. The post Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval appeared first on MedCity News.

FDA 342

More Trending

article thumbnail

Big Pharma’s most improved drugs: a new generation of blockbusters

PharmaVoice

The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.

article thumbnail

Takeda wagers up to $2.2bn on AC Immune Alzheimer’s shot

pharmaphorum

Takeda has made a strong play for a stake in the Alzheimer’s disease market, paying $100 million upfront for an option on AC Immune’s amyloid-targeting immunotherapy. The option fee could be followed by another up to $2.1 billion in potential milestones if Takeda takes global rights to the programme, currently headed by ACI-24.060 which is in a phase 1b/2 trial with new data due in the next few weeks.

Marketing 132
article thumbnail

Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says

MedCity News

While adopting new technology is obviously a big part of healthcare innovation teams’ work, there are plenty of worthwhile initiatives that don’t involve advanced technologies, pointed out Dan Shoenthal, chief innovation officer at MD Anderson Cancer Center. The post Innovation Doesn’t Always Have To Involve The Latest Tech, MD Anderson Exec Says appeared first on MedCity News.

article thumbnail

Lonza, busy with capacity upgrades and exec turnover, hints at CDMO industry rebound

Fierce Pharma

A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. | With a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that a CDMO industry stabilization is playing out.

article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Why H5N1 has scientists and regulators on edge

PharmaVoice

The strange — and difficult — aspects of the recent influenza outbreak in cattle and its potential threat to humans.

130
130
article thumbnail

Leading Sales Teams To Global Success: A Mother’s Day Special With Sydney Selby

Evolve Your Success

A Mother’s Day special! Join us as we sit down with Sydney Selby , the innovative Vice President of Sales, Marketing, and Medical Education at Renata Medical , during a week when we honor mothers and the gifts they bring into our lives. Sydney illuminates the often-invisible struggles within pediatric congenital heart disease treatment, revealing how Renata Medical’s Minima Renata stent system is revolutionizing care for the tiniest hearts.

article thumbnail

SmarterDx Rakes In $50M For Its AI That Helps Hospitals Capture More Revenue

MedCity News

SmarterDx — an AI startup that provides clinical review and quality audits for medical claims — closed a $50 million Series B funding round, bringing its total funding to date to $71 million. The post SmarterDx Rakes In $50M For Its AI That Helps Hospitals Capture More Revenue appeared first on MedCity News.

Medical 340
article thumbnail

Bayer slashed 1,500 roles in Q1 as simpler organization takes shape

Fierce Pharma

When Bayer unveiled a restructuring in January, the company didn’t provide specifics on the number of planned job cuts. | When Bayer unveiled a restructuring in January, the company didn't provide specifics on the number of planned job cuts. Now, the size of the initial round of cuts shows that CEO Bill Anderson means business.

256
256
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Investors put $400M into biotech licensing obesity drugs from China

PharmaVoice

The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.

article thumbnail

The Role of VR in Medical Device Marketing

Infuse Medical

Definition of VR Virtual Reality (VR) refers to a computer-generated simulation of an environment or experience that immerses users in a three-dimensional, interactive world. Through the use of specialized hardware, such as VR headsets or goggles, and software applications, users can perceive and interact with this digital environment as if they were physically present within it.

Medical 130
article thumbnail

DOJ Launches Task Force on Healthcare Monopolies: Will It Make A Difference?

MedCity News

The U.S. Department of Justice recently launched a task force on healthcare monopolies. Experts have varying opinions on how it will impact the healthcare industry. The post DOJ Launches Task Force on Healthcare Monopolies: Will It Make A Difference? appeared first on MedCity News.

article thumbnail

Shionogi's antiviral comes up short in global COVID-19 trial

Fierce Pharma

While much of the fanfare around COVID-19 treatments has dissipated, Shionogi has continued to press on in hopes that its Japan-approved protease inhibitor ensitrelvir could compete on a global sta | While much of the fanfare around COVID-19 treatments has dissipated, Shionogi has continued to press on in hopes that its Japan-approved protease inhibitor ensitrelvir could compete on a global stage.

253
253
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Big Pharma leaders juggle pricing and access as IRA and supply constraints loom large

PharmaVoice

Execs from J&J, Novartis, Novo Nordisk and AbbVie sound off on the Inflation Reduction Act, supply issues and launch preparations in a tricky environment.

Pharma 130
article thumbnail

Liverpool and McMaster University announce £300,000 institutional strategic research partnership

PharmaTimes

Areas include health research across life stages, from paediatrics to health ageing and resilience

Education 126
article thumbnail

Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck

MedCity News

Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody’s target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi. The post Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck appeared first on MedCity News.

article thumbnail

FDA snubs another China-made PD-1 with rejection of Elevar, Hengrui's liver cancer combo

Fierce Pharma

China-made PD-1 inhibitors just can’t get a clean pass through the FDA. | China-made PD-1 inhibitors continue to struggle at the FDA. This week, the U.S. agency rejected Elevar Therapeutics and Jiangsu Hengrui Pharma's PD-1 combination in liver cancer.

FDA 252
article thumbnail

The GTM Intelligence Era: ZoomInfo 2025 Customer Impact Report

ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!

article thumbnail

As Lilly surges, headwinds against its weight loss drugs are growing

PharmaVoice

After missing analysts’ earnings expectations for Mounjaro sales in the first quarter due to overwhelming demand, Lilly is also dealing with a legal loss and incoming pricing questions from lawmakers.

Sales 130
article thumbnail

Closed Loop and Pharmanovia investigate precision medicine combination in hypertension

PharmaTimes

The OptiZest study aims to investigate a personalised dose of Zestril in these patients

Medicine 124
article thumbnail

Right-to-Repair Laws Could Threaten Healthcare Safety

MedCity News

Healthcare devices must be exempted from general right to repair legislation. The post Right-to-Repair Laws Could Threaten Healthcare Safety appeared first on MedCity News.

Safety 321
article thumbnail

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months

Fierce Pharma

It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). | It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). And now, it’ll take another three months for the United States regulator to decide on the treatment for the endocrine disease hypoparathyroidism.

FDA 251
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

Biosimilars are gaining ground. The IRA could push them even further next year.

PharmaVoice

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

Marketing 130
article thumbnail

Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients

PharmaTimes

The cardiovascular disease, pulmonary arterial hypertension, affects around 6,500 people in the UK

Patients 124
article thumbnail

Healthcare’s Next Void to Fill: Digital Primary Care

MedCity News

No matter what form they take, one thing is clear — there is an urgent demand for digital primary care providers to guide patient navigation in the digital health era. The post Healthcare’s Next Void to Fill: Digital Primary Care appeared first on MedCity News.

Patients 321